Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRHR1 | P34998 | 4/20 | 0.41 |
| ▸ | MERTK | Q12866 | 5/20 | 0.40 |
| ▸ | AXL | P30530 | 1/20 | 0.40 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.40 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.37 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.36 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.36 |
| ▸ | SLC34A1 | Q06495 | 2/20 | 0.36 |
| ▸ | CNR1 | P21554 | 1/20 | 0.36 |
| ▸ | CNR2 | P34972 | 1/20 | 0.36 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1989809 | 1.00 | CRHR1 (0.41) | CRHR1MERTKAXLTYRO3GRM2 | |
| SCHEMBL25745791 | 0.87 | CRHR1 (0.42) | CRHR1GRM2SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL24007545 | 0.86 | CRHR1 (0.43) | CRHR1MERTKAXLTYRO3GRM2 | |
| SCHEMBL27326744 | 0.83 | SLC6A2 (0.41) | CRHR1MERTKGRM2SLC6A2SLC6A4 | |
| SCHEMBL25745792 | 0.83 | CRHR1 (0.39) | CRHR1GRM2SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL1847258 | 0.77 | CRHR1 (0.52) | CRHR1MERTKAXLTYRO3 | |
| SCHEMBL1847257 | 0.77 | CRHR1 (0.52) | CRHR1MERTKAXLTYRO3 | |
| SCHEMBL27326738 | 0.77 | SLC6A2 (0.43) | CRHR1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL1853408 | 0.76 | CRHR1 (0.42) | CRHR1SLC34A1CNR1CNR2 | |
| SCHEMBL1853407 | 0.76 | CRHR1 (0.42) | CRHR1SLC34A1CNR1CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2323970-B1 | CYCLOHEXYL AMIDE DERIVATIVES AND THEIR USE AS CRF-1 RECEPTOR ANTAGONISTS | NOVARTIS AG (CH) | 2016-04-20 | — | — | EP | disclosed |
| CN-102143940-B | Cyclohexyl amide derivatives as CRF-1 receptor antagonists and uses thereof | NOVARTIS AG | 2014-04-16 | — | — | CN | disclosed |
| US-20140088105-A1 | Cyclohexyl Amide Derivatives and Their Use as CRF-1 Receptor Antagonists | NOVARTIS AG (CH) | 2014-03-27 | — | — | US | disclosed |
| US-8614213-B2 | Cyclohexyl amide derivatives and their use as CRF-1 receptor antagonists | NOVARTIS AG (CH) | 2013-12-24 | — | — | US | disclosed |
| US-8273900-B2 | Organic compounds | NOVARTIS AG (CH) | 2012-09-25 | — | — | US | disclosed |
| US-20110152261-A1 | Organic compounds | NOVARTIS AG (CH) | 2011-06-23 | — | — | US | disclosed |
| EP-2323970-A1 | CYCLOHEXYL AMIDE DERIVATIVES AND THEIR USE AS CRF-1 RECEPTOR ANTAGONISTS | Novartis AG (CH) | 2011-05-25 | — | — | EP | disclosed |
| WO-2010015655-A1 | CYCLOHEXYL AMIDE DERIVATIVES AND THEIR USE AS CRF-1 RECEPTOR ANTAGONISTS | NOVARTIS AG (CH) | 2010-02-11 | — | — | WO | disclosed |
| US-20100035898-A1 | Organic compounds | NOVARTIS AG (CH) | 2010-02-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100035898-A1 | Organic compounds | CRH, CRHR1, CRHR2 | CRHR1 2/4885MERTK 4041/4885AXL 549/4885 |
| US-20110152261-A1 | Organic compounds | CRH, CRHR1, CRHR2 | CRHR1 2/4885MERTK 4069/4885AXL 578/4885 |
| US-20140088105-A1 | Cyclohexyl Amide Derivatives and Their Use as CRF-1 Receptor Antagonists | CRHR1, CRH, CRHR2 | CRHR1 1/4885MERTK 3130/4885AXL 855/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.